Paving the Way for Biomedical Innovation

The Frederick National Laboratory meets the nation’s most urgent biomedical research needs and serves as a national and global resource for the scientific community. 

Women in Science Speak builds community for fifth straight year

Scientists, students, and community members united for the Women in Science Speak panel in February, marking International...

Cancer Moonshot Biobank surpasses 1,000 enrollments

The National Cancer Institute’s Cancer Moonshot Biobank SM recently exceeded its initial goal of 1,000 enrolled participants...

Scientists report new method for finding a tuberculosis vaccine

No vaccine reliably prevents tuberculosis, but new research has demonstrated a strategy for developing a vaccine that could...

Multi-laboratory study demonstrates high agreement among molecular tumor tests

A recent study of 26 laboratories across the United States revealed high concordance between next-generation sequencing tumor...

Biotech Connector reimagines the future of gene and cell-based therapies

The recent Biotech Connector showcased exciting advancements in gene and cell-based therapies in the Frederick area. More...

Exploiting cellular degradation machinery as a potential treatment strategy for RAS-driven cancers

Exploiting a cell’s built-in mechanism to degrade and destroy proteins is a promising strategy to combat RAS-driven cancers...

International study results show need for universal set of quality control materials for liquid biopsies

A public-private partnership including scientists from the Frederick National Laboratory for Cancer Research determined...
What is this?

Semi-automated inspection of drug product. The Vaccine Clinical Materials Program supports the National Institute of Allergy and Infectious Diseases Vaccine Research Center in the development, production, and supply of investigational-phase biologics and/or vaccine candidates to address infectious diseases of global importance. The program provides a complete life cycle for clinical materials from cell banking, drug substance, and drug product filling and testing.

Information
Initiative

RAS Initiative

The RAS Initiative mobilizes the cancer research community to develop ways to treat cancers driven by the mutant RAS gene in an open model of collaboration among government, academic, and industry researchers.
220,000
People per year in the U.S. are diagnosed with cancers caused by KRAS mutations.
What is this? Surface representation of the structure of an oncogenic mutant of KRAS in complex with RAS-binding domains of RAF1 Kinase. The GMPPNP bound to oncogenic KRAS mutant is shown in ball-and-stick representation.
Information
Initiative

Scientific Standards Hub

Our scientists establish standards and reference reagents for diverse scientific  disciplines and  encourage the adoption of benchmarks  among researchers. 
8
disciplines with tools to help bridge gaps in scientific reproducibility.

Our Passion is Infectious

Shape Your Career

Work with the best of the best biomedical researchers and investigators. Be a part of groundbreaking solutions that benefit public health throughout the world. And, enjoy some of the best benefits in the region. We are looking for smart, passionate problem solvers for benchwork, data science, manufacturing, and more.